
|Videos|October 23, 2017
Dr. Geynisman Discusses Immunotherapy in RCC
Author(s)Daniel M. Geynisman, MD
Daniel M. Geynisman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses immunotherapy in metastatic renal cell carcinoma.
Advertisement
Daniel M. Geynisman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses immunotherapy in metastatic renal cell carcinoma (mRCC).
Patients are excited and willing to participate in clinical trials of immunotherapy, says Geynisman. In RCC, select patients have shown to derive benefit from immunotherapy.
Geynisman says that trials of immunotherapy and targeted therapies will undoubtedly change the treatment paradigm in mRCC.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
3
Outcomes With Bridging Therapy Correlate With Cilta-Cel Efficacy, Safety in Multiple Myeloma
4
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
5






































